Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. GlaxoSmithKline
WARNING LETTER
•GlaxoSmithKline•November 13, 2007

GlaxoSmithKline – FDA Warning Letter, Nov 13, 2007

Record Details

An FDA inspection conducted from August 20 to November 13, 2007, at GlaxoSmithKline's corporate headquarters in Research Triangle Park, NC, focused on Postmarketing Adverse Drug Experience (PADE) and other postmarketing reporting requirements for Avandia (rosiglitazone maleate), NDA 21-071. The inspection revealed the firm failed to report clinical experience data and other information as required by Section 505(k)(1) of the Federal Food, Drug, and Cosmetic Act and 21 CFR Sections 314.80 and 314.81. Specific violations included incomplete Periodic Reports lacking a history of actions taken due to adverse drug experiences (21 CFR 314.80(c)(2)(ii)(c)), and incomplete Annual Reports from 2001-2007 that failed to include status reports for numerous postmarketing studies (21 CFR 314.81(b)(2)(viii)) and the status of the ADOPT study in the 2007 report (21 CFR 314.81(b)(2)(vii)). The FDA noted GSK lacked appropriate knowledge of Avandia studies, leading to these deficiencies. GSK's response to the Form FDA 483 was deemed inadequate, failing to explain how the firm would ensure submission of all mandatory postmarketing reporting information for its approved drug products. The FDA expects comprehensive corrective actions, including an evaluation of reporting for all approved drug products. Failure to correct these serious violations may result in regulatory actions, impact federal contracts, and delay approval of pending applications. A written response detailing corrective actions and prevention of recurrence is required within fifteen working days.

Company
GlaxoSmithKline
Inspection date
November 13, 2007
Product type
Drugs
Office
Atlanta District Office
People
  • Mary H. Woleske
  • Philip S. Campbell
  • Edward N. Pattishall
View Company Profile

ID · f477aa59-1232-4ce5-838b-6daaf9cf8b6d

Violation Codes7
21 U.S.C. 355(k)(1)21 U.S.C. 331(e)21 CFR 314.80(c)(2)(ii)(c)21 CFR 314.81(b)(2)(viii)21 CFR 314.81(b)(2)(vii)21 CFR 314.8021 CFR 314.81

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore GlaxoSmithKline
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.